|
|
||||||||



*
Immunogenetics and Transplantation Laboratory, Department of Surgery, University of California, San Francisco, CA 94143;
Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114; and
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322
We analyzed CD4+ T helper responses to wild-type (wt) and mutated (mut) p53 protein in normal and tumor-bearing mice. In normal mice, we observed that although some self-p53 determinants induced negative selection of p53-reactive CD4+ T cells, other p53 determinants (cryptic) were immunogenic. Next, BALB/c mice were inoculated with J774 syngeneic tumor cell line expressing mut p53. BALB/c tumor-bearing mice mounted potent CD4+ T cell responses to two formerly cryptic peptides on self-p53. This response was characterized by massive production of IL-5, a Th2-type lymphokine. Interestingly, we found that T cell response was induced by different p53 peptides depending upon the stage of cancer. Mut p53 gene was shown to contain a single mutation resulting in the substitution of a tyrosine by a histidine at position 231 of the protein. Two peptides corresponding to wt and mutated sequences of this region were synthesized. Both peptides bound to the MHC class II-presenting molecule (Ed) with similar affinities. However, only mut p53.225239 induced T cell responses in normal BALB/c mice, a result strongly suggesting that high-affinity wt p53.225239 autoreactive T cells had been eliminated in these mice. Surprisingly, CD4+ T cell responses to both mut and wt p53.225239 peptides were recorded in J774 tumor-bearing mice, a phenomenon attributed to the recruitment of low-avidity p53.225239 self-reactive T cells.
This article has been cited by other articles:
![]() |
A. P. Castano, P. Mroz, M. X. Wu, and M. R. Hamblin Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model PNAS, April 8, 2008; 105(14): 5495 - 5500. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Lauwen, S. Zwaveling, L. de Quartel, S. C. Ferreira Mota, J. A.C. Grashorn, C. J.M. Melief, S. H. van der Burg, and R. Offringa Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen Cancer Res., February 1, 2008; 68(3): 893 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Charalambous, M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin J. Immunol., December 15, 2006; 177(12): 8410 - 8421. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Radosevich, Z. Song, J. C. Gorga, B. Ksander, and S. J. Ono Epigenetic Silencing of the CIITA Gene and Posttranscriptional Regulation of Class II MHC Genes in Ocular Melanoma Cells Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 3185 - 3195. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Espenschied, J. Lamont, J. Longmate, S. Pendas, Z. Wang, D. J. Diamond, and J. D. I. Ellenhorn CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model J. Immunol., March 15, 2003; 170(6): 3401 - 3407. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zwaveling, M. P. M. Vierboom, S. C. Ferreira Mota, J. A. Hendriks, M. E. Ooms, R. P. M. Sutmuller, K. L. M. C. Franken, H. W. Nijman, F. Ossendorp, S. H. van der Burg, et al. Antitumor Efficacy of Wild-Type p53-specific CD4+ T-Helper Cells Cancer Res., November 1, 2002; 62(21): 6187 - 6193. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. van der Burg, A. G Menon, A. Redeker, M.-C. Bonnet, J. W. Drijfhout, R. A. E. M. Tollenaar, C. J. H. van de Velde, P. Moingeon, P. J. K. Kuppen, R. Offringa, et al. Induction of p53-specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine Clin. Cancer Res., May 1, 2002; 8(5): 1019 - 1027. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yasuda, M. Takenoyama, Y. Obata, M. Sugaya, T. So, T. Hanagiri, K. Sugio, and K. Yasumoto Tumor-infiltrating B Lymphocytes as a Potential Source of Identifying Tumor Antigen in Human Lung Cancer Cancer Res., March 1, 2002; 62(6): 1751 - 1756. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |